1. Home
  2. ZURA vs CNTX Comparison

ZURA vs CNTX Comparison

Compare ZURA & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZURA
  • CNTX
  • Stock Information
  • Founded
  • ZURA 2022
  • CNTX 2015
  • Country
  • ZURA United States
  • CNTX United States
  • Employees
  • ZURA N/A
  • CNTX N/A
  • Industry
  • ZURA Biotechnology: Biological Products (No Diagnostic Substances)
  • CNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZURA Health Care
  • CNTX Health Care
  • Exchange
  • ZURA Nasdaq
  • CNTX Nasdaq
  • Market Cap
  • ZURA 69.9M
  • CNTX 78.0M
  • IPO Year
  • ZURA N/A
  • CNTX 2021
  • Fundamental
  • Price
  • ZURA $1.31
  • CNTX $0.69
  • Analyst Decision
  • ZURA Buy
  • CNTX Strong Buy
  • Analyst Count
  • ZURA 7
  • CNTX 5
  • Target Price
  • ZURA $14.33
  • CNTX $5.50
  • AVG Volume (30 Days)
  • ZURA 708.2K
  • CNTX 151.1K
  • Earning Date
  • ZURA 08-08-2025
  • CNTX 08-06-2025
  • Dividend Yield
  • ZURA N/A
  • CNTX N/A
  • EPS Growth
  • ZURA N/A
  • CNTX N/A
  • EPS
  • ZURA N/A
  • CNTX N/A
  • Revenue
  • ZURA N/A
  • CNTX N/A
  • Revenue This Year
  • ZURA N/A
  • CNTX N/A
  • Revenue Next Year
  • ZURA N/A
  • CNTX N/A
  • P/E Ratio
  • ZURA N/A
  • CNTX N/A
  • Revenue Growth
  • ZURA N/A
  • CNTX N/A
  • 52 Week Low
  • ZURA $0.97
  • CNTX $0.49
  • 52 Week High
  • ZURA $5.07
  • CNTX $2.75
  • Technical
  • Relative Strength Index (RSI)
  • ZURA 59.63
  • CNTX 57.14
  • Support Level
  • ZURA $1.00
  • CNTX $0.62
  • Resistance Level
  • ZURA $1.45
  • CNTX $0.67
  • Average True Range (ATR)
  • ZURA 0.10
  • CNTX 0.05
  • MACD
  • ZURA 0.03
  • CNTX 0.01
  • Stochastic Oscillator
  • ZURA 68.89
  • CNTX 89.29

About ZURA Zura Bio Limited

Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Share on Social Networks: